FY2026 Earnings Estimate for MDGL Issued By HC Wainwright

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – Equities research analysts at HC Wainwright issued their FY2026 earnings per share estimates for shares of Madrigal Pharmaceuticals in a report issued on Wednesday, November 4th. HC Wainwright analyst A. Ghosh expects that the biopharmaceutical company will post earnings of ($2.37) per share for the year. HC Wainwright currently has a “Strong-Buy” rating on the stock. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($6.88) per share. HC Wainwright also issued estimates for Madrigal Pharmaceuticals’ Q4 2026 earnings at $0.95 EPS, FY2027 earnings at $8.29 EPS, FY2028 earnings at $29.07 EPS, FY2029 earnings at $43.84 EPS and FY2030 earnings at $71.25 EPS.

Several other equities analysts also recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a report on Thursday, October 15th. The Goldman Sachs Group initiated coverage on shares of Madrigal Pharmaceuticals in a research note on Thursday, September 24th. They set a “buy” rating and a $704.00 price target for the company. UBS Group reissued a “buy” rating and issued a $735.00 price objective on shares of Madrigal Pharmaceuticals in a research note on Wednesday, October 14th. Wells Fargo & Company started coverage on Madrigal Pharmaceuticals in a report on Monday, July 27th. They set an “overweight” rating and a $685.00 price objective on the stock. Finally, Canaccord Genuity Group lifted their target price on Madrigal Pharmaceuticals from $612.00 to $633.00 and gave the company a “buy” rating in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $706.87.

Madrigal Pharmaceuticals Trading Down 0.1%

Madrigal Pharmaceuticals stock opened at $400.10 on Friday. Madrigal Pharmaceuticals has a 12-month low of $353.54 and a 12-month high of $615.00. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.94 and a current ratio of 3.05. The firm has a 50-day moving average price of $489.63 and a 200-day moving average price of $497.94.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.09) by $2.92. Madrigal Pharmaceuticals had a negative net margin of 10.89% and a negative return on equity of 27.08%. The business had revenue of $431.27 million for the quarter, compared to analysts’ expectations of $404.17 million. During the same quarter in the previous year, the business posted ($5.08) earnings per share.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Janus Henderson Group PLC lifted its holdings in shares of Madrigal Pharmaceuticals by 27.4% during the first quarter. Janus Henderson Group PLC now owns 2,018,647 shares of the biopharmaceutical company’s stock worth $1,051,727,000 after purchasing an additional 433,804 shares during the period. Jupiter Topco LLC acquired a new position in Madrigal Pharmaceuticals in the 2nd quarter worth approximately $1,039,650,000. Paulson & CO. Inc. acquired a new position in Madrigal Pharmaceuticals in the 2nd quarter worth approximately $719,524,000. BlackRock Inc. acquired a new position in Madrigal Pharmaceuticals in the 2nd quarter worth approximately $644,753,000. Finally, Wellington Management Group LLP increased its holdings in Madrigal Pharmaceuticals by 18.8% in the 2nd quarter. Wellington Management Group LLP now owns 825,714 shares of the biopharmaceutical company’s stock worth $443,367,000 after buying an additional 130,756 shares during the period. Institutional investors own 98.50% of the company’s stock.

Insider Activity

In other Madrigal Pharmaceuticals news, General Counsel Shannon Kelley sold 664 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $514.97, for a total transaction of $341,940.08. Following the transaction, the general counsel owned 11,474 shares of the company’s stock, valued at approximately $5,908,765.78. This trade represents a 5.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO William Sibold sold 6,362 shares of the business’s stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $535.59, for a total transaction of $3,407,423.58. Following the completion of the sale, the chief executive officer owned 202,967 shares of the company’s stock, valued at approximately $108,707,095.53. This represents a 3.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 12,247 shares of company stock worth $6,581,182. 17.60% of the stock is owned by company insiders.

Key Madrigal Pharmaceuticals News

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Rezdiffra real-world data showed improvements in liver stiffness and cardiometabolic health markers. Madrigal presented results from multiple studies at the AASLD meeting, offering further evidence supporting the drug’s use in MASH. Recent coverage also cited Rezdiffra sales of about $1.1 billion. Madrigal real-world data announcement
• Positive Sentiment: Strong results and optimistic forecasts support the growth outlook. Madrigal reported quarterly EPS of $1.83, versus analysts’ expected loss of $1.09, and revenue of $431.27 million, ahead of estimates. HC Wainwright reiterated a Strong-Buy rating and forecast EPS growth from a 2026 loss to $8.29 in 2027 and $71.25 in 2030. Canaccord also raised its price target to $633 and maintained a Buy rating. Coverage of Madrigal’s post-earnings move Canaccord analyst coverage
• Negative Sentiment: Several law firms announced investigations into possible securities-law violations. The notices could add uncertainty and weigh on sentiment, but they are announcements of investigations and do not establish that Madrigal or its executives violated the law. Kaplan Fox investigation notice

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for nonalcoholic steatohepatitis, now known as metabolic dysfunction-associated steatohepatitis (MASH), and other chronic liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal’s lead product is Rezdiffra (resmetirom), an orally administered thyroid hormone receptor beta agonist designed to target key drivers of liver disease, including hepatic fat accumulation and fibrosis.